AZ bets big on biologics with $285M Swedish facility

AstraZeneca ($AZN), trying to turn its sales performance around, has some biologics launches on the horizon. But to accommodate them, it needs more manufacturing capacity, and it thinks a new $285 million plant in Sweden will do the trick. More from FiercePharma

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.